Global Acute Myeloid Leukemia Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Acute Myeloid Leukemia Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Disease Type (Myeloblastic Leukemia, Myelomonocytic Leukemia, Promyelocytic Leukemia, Monocytic Leukemia, and Others), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), Route of Administration (Parental, and Oral), End User (Hospitals and Clinics, Specialty Centers, Homecare Settings, and Ambulatory Care Centers), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Acute Myeloid Leukemia Market was valued at USD 2,915.7 million in 2023 and is expected to reach USD 6,915.4 million by 2031 while growing at a CAGR of 11.4% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global acute myeloid leukemia market growth. Acute myeloid leukemia (AML) originates in the bone marrow but typically rapidly disseminates into the bloodstream. Occasionally, it may metastasize to other organs such as the lymph nodes, liver, spleen, central nervous system (including the brain and spinal cord), and testicles.
Advancements in treatment modalities, the rising incidence of AML, and government initiatives and funding are driving market growth. However, the high cost of treatment and regulatory challenges pose significant barriers to further expansion.
Furthermore, the global acute myeloid leukemia industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Disease Type Analysis
The Global Acute Myeloid Leukemia Market is segmented among Myeloblastic Leukemia, Myelomonocytic Leukemia, Promyelocytic Leukemia, Monocytic Leukemia, and Others, based on Disease Type. In 2023, Myeloblastic Leukemia accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Treatment Type Analysis
The Global Acute Myeloid Leukemia Market is segmented among Chemotherapy, Targeted Therapy, Immunotherapy, and Others, based on Treatment Type. In 2023, Chemotherapy accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Acute Myeloid Leukemia Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Partner Therapeutics, Inc., Pfizer Inc., and Rigel Pharmaceuticals, Inc.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Acute Myeloid Leukemia Market Dynamics
Drivers
Restraints
Opportunity
4. Global Acute Myeloid Leukemia Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Acute Myeloid Leukemia Market Segmentation, By Disease Type
Global Acute Myeloid Leukemia Market Share Analysis, By Disease Type
Global Acute Myeloid Leukemia Market Growth Analysis, By Disease Type
Global Acute Myeloid Leukemia Market Trends, By Disease Type
o Myeloblastic Leukemia
o Myelomonocytic Leukemia
o Promyelocytic Leukemia
o Monocytic Leukemia
o Others
6. Global Acute Myeloid Leukemia Market Segmentation, By Treatment Type
Global Acute Myeloid Leukemia Market Share Analysis, By Treatment Type
Global Acute Myeloid Leukemia Market Growth Analysis, By Treatment Type
Global Acute Myeloid Leukemia Market Trends, By Treatment Type
o Chemotherapy
o Targeted Therapy
o Immunotherapy
o Others
7. Global Acute Myeloid Leukemia Market Segmentation, By Route of Administration
Global Acute Myeloid Leukemia Market Share Analysis, By Route of Administration
Global Acute Myeloid Leukemia Market Growth Analysis, By Route of Administration
Global Acute Myeloid Leukemia Market Trends, By Route of Administration
o Parental
o Oral
8. Global Acute Myeloid Leukemia Market Segmentation, By End User
Global Acute Myeloid Leukemia Market Share Analysis, By End User
Global Acute Myeloid Leukemia Market Growth Analysis, By End User
Global Acute Myeloid Leukemia Market Trends, By End User
o Hospitals and Clinics
o Specialty Centers
o Homecare Settings
o Ambulatory Care Centers
9. Global Acute Myeloid Leukemia Market Segmentation, By Region
Global Acute Myeloid Leukemia Market Share Analysis, By Region
Global Acute Myeloid Leukemia Market Growth Analysis, By Region
Global Acute Myeloid Leukemia Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
10. Competitive Landscape
Astellas Pharma Inc.*
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Bristol Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company Limited
Jazz Pharmaceuticals plc
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Partner Therapeutics, Inc.
Pfizer Inc.
Rigel Pharmaceuticals, Inc
*Similar analysis will be provided for each company listed above.
